Entrada crashes as Duchenne therapy comes in ‘below expectations’ in early study

Entrada Therapeutics saw a 2.36% dystrophin increase in patients treated with its oligonucleotide asset—a number that fell short of the company’s prior guidance of a double-digit improvement.